Edwards Lifesciences Corporation (EW) has had a turbulent time recently with some bearish and bullish developments. The company's stock has shown weakness lately, however, the financials look strong. Amidst the weak performance, there are speculation of a possible takeover, making the shares attractive to prospective investors. In a significant move, BD is set to acquire Edward Lifesciences' critical care product group to expand their offerings. This has resulted in global layoffs and a lowering of Edward Lifesciences' EPS. However, their Q4 and full year 2023 results showed robust financial performance, and despite an overall decline in the last year, their underlying 3-year earnings growth is promising. This strong institutional backing is reflected by their 85% institutional ownership. Edward Lifesciences recently acquired Innovalve to boost their TMVR solutions, and have completed the sale of their critical care group to BD. This happened alongside a divestiture of their critical care wing, and a surprise $4.2 billion deal. However, the slowdown in TAVR Business has led to a drop in the value of EW's stock. Despite this, Edward Lifesciences is expected to possibly beat Q1 earnings. Amidst these developments, the company has reaffirmed its focus on heart devices.
Edwards Lifesciences Corp EW News Analytics from Thu, 07 Dec 2023 08:00:00 GMT to Sat, 05 Oct 2024 16:32:01 GMT -
Rating -2
- Innovation 0
- Information 4
- Rumor -3
